Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating XC221 for safety and efficacy in uncomplicated influenza and other acute viral upper respiratory infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Viral Infection

Drugs mentioned

• XC221

Snippet

Sponsor: Valenta Pharm JSC | Conditions: Influenza, Respiratory Viral Infection | Phase 3 | Status: COMPLETED